UNBS.F Stock Overview
An investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Uni-Bio Science Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.004 |
| 52 Week High | HK$0.004 |
| 52 Week Low | HK$0.004 |
| Beta | -0.14 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| UNBS.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how UNBS.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how UNBS.F performed against the US Market.
Price Volatility
| UNBS.F volatility | |
|---|---|
| UNBS.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: UNBS.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine UNBS.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 458 | Frank Zhao | www.uni-bioscience.com |
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates in Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Boshutai, a small molecule drug to treat diabetes.
Uni-Bio Science Group Limited Fundamentals Summary
| UNBS.F fundamental statistics | |
|---|---|
| Market cap | US$48.35m |
| Earnings (TTM) | US$12.71m |
| Revenue (TTM) | US$65.34m |
3.8x
P/E Ratio0.7x
P/S RatioIs UNBS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UNBS.F income statement (TTM) | |
|---|---|
| Revenue | HK$508.40m |
| Cost of Revenue | HK$83.85m |
| Gross Profit | HK$424.55m |
| Other Expenses | HK$325.70m |
| Earnings | HK$98.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.017 |
| Gross Margin | 83.51% |
| Net Profit Margin | 19.44% |
| Debt/Equity Ratio | 26.5% |
How did UNBS.F perform over the long term?
See historical performance and comparison